DDDeepa Mbbs Devi

Deepa Mbbs Devi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Deepa Mbbs Devi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Emergent coronary angiography in patients with out-of-hospital cardiac arrest: a systematic review and meta-analysis

    by Aima Mbbs Azhar, Saad Mbbs Mazhar, Fasih Mand Mbbs Khan, Humera Raja Mbbs Azhar, Syeda Wafa Mbbs Zahra, Deepa Mbbs Devi, Sapna Mbbs Kumari, Fnu Mbbs Nisha, Neha Mbbs Kumar, Umer Mbbs Ejaz, et al.

    Background: Early coronary angiography (CAG) is a subject of controversy in post-cardiac arrest patients who do not exhibit ST-segment elevation. The objective of this meta-analysis was to evaluate the effect it had on outcomes. Methods: A comprehensive search of Medline and Cochrane yielded 16 studies [of which 9 were observational and 7 were randomized controlled trials (RCTs)] involving 4737 patients. 95% confidence intervals accompanied odds ratios (ORs) were generated by a random-effects model. Meta-regression explored factors modifying effect sizes. Results: Early coronary angiography (CAG) decreased long-term mortality significantly [OR: 0.66 (0.51–0.85)], improved favorable coronary prothrombotic scores [Cerebral Performance Category (CPC) 1–2] at discharge [OR: 1.49 (1.09–2.03)], and suggested a trend toward increased percutaneous coronary intervention after CAG [OR: 1.07 (0.75–1.53)]. In contrast to the RCT subgroup, the observational study subgroup exhibited reduced rates of short- and long-term mortality, as well as CPC1–2 at discharge. Meta-regression revealed that type 2 diabetes mellitus and follow-up time influence short-term mortality and CPC 1–2 at discharge, respectively. Conclusion: Observational studies demonstrated that early CAG in post-cardiac arrest patients without ST elevation is associated with long-term clinical benefits. Caveat should be exercised when interpreting.

  • Open Access

    Factor Xa inhibitors vs. warfarin in patients with Hughes syndrome: a systematic review and meta-analysis of randomized controlled trials

    by Ali Mbbs Mohtashim, Aima Mbbs Azhar, Saad Mbbs Mazhar, Deepa Mbbs Devi, Muhammad Mbbs Danial, Dhruvilkumar Mbbs Patel, Owais Mbbs Khan, Anushka Mbbs Andani, Muhammad Mohib Mbbs Khan, Shahzaib Mbbs Samad, et al.

    Background: The optimal treatment regimen for patients with Hughes syndrome remains unclear. Therefore, the authors sought to compare the outcomes of warfarin vs. factor Xa inhibitors in patients with Hughes syndrome. Methods: MEDLINE, Embase, and Cochrane Central databases were searched for randomized controlled trials (RCTs) comparing 8 efficacy and safety of warfarin and factor Xa inhibitors in patients with Hughes syndrome. Recurrent thrombosis, all-cause mortality, stroke, adverse reactions, and bleeding were among 10 outcomes of interest. Mantel–Haenszel weighted random-effects model was used to calculate 11 relative risks (RRs) with 95% CIs. Results: The analysis included 625 patients from four RCTs and one post-hoc analysis. Meta-analysis showed a statistically non-significant difference between factor Xa inhibitors and warfarin in the recurrent thrombosis risk (arterial or venous) [RR 2.77 (95%, CI 0.79, 9.65); P=0.11, I2=50%]. Consistent results were revealed among patients with a previous history of arterial thrombosis [RR 2.76 (95% CI 0.93, 8.16); P=0.75, I2=0%], venous thrombosis [RR 1.71 (95% CI 0.60, 4.84); P=0.31, I2=15%] and patients who were triple antiphospholipid antibodies (aPL) positive [RR 4.12 (95% CI 0.46, 37.10); 21 P=0.21, I2=58%]. Factor Xa inhibitors were significantly associated with an increased risk of stroke [RR 8.51 (95% CI 2.35, 13.82); P=0.47, I2=0%]. Conclusion: Factor Xa inhibitors exhibited an increased risk of stroke among patients with Hughes syndrome. In addition, although not significant, the higher RRs among patients on factor Xa inhibitors may indicate a higher risk of thrombotic events associated with factor Xa inhibitors.